SCLC refers to small cell lung cancer, an aggressive, fast-growing lung malignancy that tends to spread earlier than non-small cell lung cancer. It is clinically distinct from NSCLC and often presents with rapid progression.
Alliance launches Phase III trial for stage I NSCLC immunotherapy; Allarity starts Phase 2 SCLC trial. Phase I NSCLC trial sites consolidate at top U.S. sites, prompting FDA representation concerns.
Researchers identified three distinct molecular phenotypes of small cell lung cancer that could help stratify patients for targeted therapy. Only patients with ANXA1Low infiltrated phenotype derived significant survival benefit from chemotherapy plus immune checkpoint inhibitors. Separate research found that targeting epigenetic regulators like PRC2 and G9a/GLP could enhance treatment efficacy.
GSK's antibody-drug conjugate risvutatug rezetecan has received Orphan Drug Designation in Japan for small-cell lung cancer, marking its sixth global regulatory designation. The decision was based on phase I trial data showing durable responses in extensive-stage SCLC patients. The drug is currently in phase III development for relapsed ES-SCLC.
Two recent clinical trials found that adding immunotherapy to standard chemoradiation did not improve survival for patients with limited-stage small-cell lung cancer or high-risk HPV-positive oropharyngeal cancer, though both studies revealed important insights about treatment delivery and radiation scheduling.
Scientists at three institutions have developed distinct nanoparticle-based drug delivery systems designed to target cancer tumors more precisely while reducing side effects, with approaches ranging from DNA nanomachines to transformable nanofibers.
Edgewise Therapeutics and IDEAYA Biosciences released annual financial reports detailing clinical trial progress and strategic initiatives. Both companies are advancing multiple clinical-stage programs while managing significant operating expenses.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07535359 |
Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer |
AVAILABLE | |
| NCT07508852 |
68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer |
RECRUITING | PHASE1/PHASE2 |
| NCT07416695 |
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC |
RECRUITING | PHASE1 |
| NCT07145333 |
Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms |
ACTIVE_NOT_RECRUITING | PHASE2/PHASE3 |
| NCT07110103 |
Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC |
RECRUITING | PHASE2 |
| NCT06820762 |
Irinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study |
NOT_YET_RECRUITING | PHASE2 |
| NCT06771219 |
SLV-154 Treatment of Metastatic Solid Tumors |
RECRUITING | PHASE1 |
| NCT06727370 |
Cognitive Screening in Lung Cancer Patients |
RECRUITING | |
| NCT06657222 |
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors |
RECRUITING | PHASE1/PHASE2 |
| NCT06616532 |
PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer |
ACTIVE_NOT_RECRUITING | PHASE3 |
